Clinical Pathway for the Diagnosis and Management of Patients With Relapsing-Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population

被引:0
作者
Caparo-Zamalloa, Cesar [1 ,2 ,3 ]
Velasquez-Rimachi, Victor [3 ,4 ,5 ]
Mori, Nicanor [3 ,6 ]
Duenas-Pacheco, Wenzel Ivan [7 ]
Huerta-Rosario, Andrely [4 ,5 ,8 ]
Farronay-Garcia, Chandel [4 ,9 ]
Molina, Roberto A. [4 ,5 ,7 ]
Alva-Diaz, Carlos [5 ]
机构
[1] Inst Nacl Ciencias Neurol, Basic Res Ctr Dementias & Cent Nervous Syst Demye, Lima, Peru
[2] Clin Delgado, Neurosonol, Lima, Peru
[3] Univ Nacl Mayor San Marcos, Fac Med, Lima, Peru
[4] Red Eficacia Clin & Sanitaria REDECS, Lima, Peru
[5] Univ Cient Sur, Grp Invest Neurociencia Efectividad Clin & Salud, Lima, Peru
[6] Hosp Daniel Alcides Carrion, Dept Med & Oficina Apoyo Docencia & Invest OADI, Serv Neurol, Callao, Peru
[7] Hosp Nacl Maria Auxiliadora, Serv Neurol, Lima, Peru
[8] Univ Nacl Federico Villarreal, Fac Med Hipolito Unanue, Lima, Peru
[9] Inst Nacl Salud INS, Lima, Peru
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
关键词
multiple sclerosis; relapsing-remitting; patient care management; critical pathways; Peru; INTRAVENOUS METHYLPREDNISOLONE; ORAL CLADRIBINE; CARE; OCRELIZUMAB; CONVERSION; TRIAL; GUIDELINE; RITUXIMAB; SAFETY; TIME;
D O I
10.3389/fneur.2021.667398
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Relapsing-remitting multiple sclerosis (RRMS) is a subtype of degenerative inflammatory demyelinating disease of multifactorial origin that affects the central nervous system and leads to multifocal neurological impairment.</p> Objectives: To develop a clinical pathway (CP) for the management of Peruvian patients with RRMS.</p> Methods: First, we performed a literature review using Medline, Embase, Cochrane, ProQuest, and Science direct. Then, we structured the information as an ordered and logical series of five topics in a defined timeline: (1) How should MS be diagnosed? (2) How should a relapse be treated? (3) How should a DMT be initiated? (4) How should each DMT be used? and (5) How should the patients be followed?</p> Results: The personnel involved in the care of patients with RRMS can use a series of flowcharts and diagrams that summarize the topics in paper or electronic format.</p> Conclusions: We propose the first CP for RRMS in Peru that shows the essential steps for diagnosing, treating, and monitoring RRMS patients based on an evidence-based medicine method and local expert opinions. This CP will allow directing relevant clinical actions to strengthen the multidisciplinary management of RRMS in Peru.</p>
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [22] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
  • [23] Tremor in Patients with Relapsing-Remitting Multiple Sclerosis: Clinical Characteristics and Impact on Quality of Life
    Shalash, Ali
    Elhodeby, Ahmed Mohamed
    Saad, Mahmoud
    Ibrahim, Yosra Abdelzaher
    Hamid, Eman
    Nasef, Ayman
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (07): : 1099 - 1106
  • [24] Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
    Onder, Halil
    TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (02) : 105 - 106
  • [25] Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
    Chan, Andrew
    de Seze, Jerome
    Comabella, Manuel
    CNS DRUGS, 2016, 30 (01) : 41 - 51
  • [26] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [27] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453
  • [28] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [29] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [30] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):